Navigation Links
'At home' genomic tests for disease risk premature
Date:3/18/2008

NEW YORK, MARCH 18, 2008--The recent marketing of at home genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC). Health professionals are now faced with the prospect of their patients coming to the office, a DNA profile in hand, asking for preventative management tailored to their specific disease risks, Dr. Offit writes in the March 19 special genomics issue of the Journal of the American Medical Association (JAMA).

In recent years, more than two dozen companies have been marketing a range of genetic tests directly to consumers concerned about genetic conditions. These conditions include those related to risks for disease, other genetic traits, and ancestry. Some of these companies have marketed whole genome scans, which provide assessments of risk for various health conditions ranging from the type of earwax an individual forms to his or her risks for diseases including cancer, diabetes, and blindness.

In his JAMA commentary, Dr Offit offers several caveats and recommendations to help doctors and counselors as they consider offering these research-based tests in clinical practice. Dr Offit voices concerns about the scientific accuracy of some of these tests, because they have not yet been validated in forward looking (prospective) clinical studies. In addition, he writes, the laboratory accuracy of these tests may vary.

A second concern voiced in the commentary is the direct to consumer aspect of the marketing of these tests, which excludes guidance from healthcare professionals. According to Dr. Offit, this limits the sources of information available to consumers about these tests and their accuracy from those marketing the tests. This critical lack of information, he says, raises concerns that patients/individuals may not have the resources to make unbiased decisions regarding whether to proceed with genetic testing.

Dr. Offit also expresses apprehension that once these self ordered test results are relayed, individuals receiving the results may not also receive counseling regarding appropriate medical interventions for prevention and early detection of genetic disorders. The article reminds readers that certain state health departments, New Yorks for instance, have indicated that genetic testing for disease risk must be requested by a licensed healthcare professional and must be performed in an approved clinical laboratory.

Dr. Offit points to recent academic and governmental reports that suggest that greater regulation is required to oversee the accuracy and quality of direct to consumer genetic testing. As one of the leaders of the clinical introduction of genetic testing for breast and colon cancer over the past decade, Dr. Offit argues for the cautious introduction of new whole genome testing, preferably in the setting of ongoing clinical trials. Those of us in the field of genetic testing for cancer risk proceeded cautiouslyThe same approach should be followed for genomic testing for other disease risks he says. Not doing so runs the risk of dangerously reassuring some and needlessly worrying the already worried well.


'/>"/>

Contact: Jeanne D'Agostino
DAgostiJ@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related biology news :

1. Fireproofing homes dramatically reduces forest fire size, according to new study
2. Homeland Security awards 2 grants to Rutgers for nuclear threat detection
3. Saltwater crocodiles can find their way home
4. Zinc may reduce pneumonia risk in nursing home elderly
5. The surprising story of Charles Darwin and his homeopathic doctor
6. Threatened bird species finds home at Western
7. Chemist Brings SAFETY Act Expertise to Homeland Security Firm
8. Selective restraints and reduced medication could reduce nursing home falls says 4-year study
9. How baby fish find a home
10. Opening day for a home of the future
11. Increased allergen levels in homes linked to asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is now offering a ... consumers who want to have their DarioHealth products reimbursed ... alliance agreements with partners across the U.S. who will ... approved, will supply and bill the customer,s insurance for ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... Business Report" report to their offering. ... This report analyzes the Global market ... estimates and forecasts are provided for the period 2014 through 2022. ... The report profiles 25 companies including many key ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
Breaking Biology Technology: